AI-generated · cited to primary sources · not investment advice
Anthem Bioscienc (544449) Nov 2025 Filing Analysis
Does management do what it says?
The company reports that 9MFY26 revenue from Specialty Ingredients (primarily produced at Unit III) is at Rs. 253.5 Cr (INR 2,535 Mn), suggesting the target for the unit is likely to be met or exceeded by year-end. (1 in progress, 2 met across 3 tracked commitments)
“Our idea would be to push this number to say Rs. 100 Cr - Rs. 150 Cr, by which time we would be supplying. This has been our strategy. We don't like to keep our plants vacant.”
Management confirmed the commissioning of the CP7 block (76 kiloliters) in Unit-2 during the last quarter. (3 met, 2 revised across 5 tracked commitments)
“Commissioning of Fermentation block expected by end of the year”
The company is committed to building one of the most agile, science-led, and future-ready CRDMO platforms in the world as it enters FY27. (+1 more commitment)
“the long-term target on this is also to deliver about 1.4x - 1.5x on asset turnover. On Rs. 450 Cr capital base, we can generate close to about Rs. 650 Cr of revenues on a long-term basis.”
The company expects to supply GLP-1 (Semaglutide) to customers in India following patent expirations next year. — target: Supply GLP-1 to Indian customers (+1 more commitment)
“We expect to be supplying the GLP-1 to our customers in India... next year when the innovator patents expire in India, at that time, during that time, this could be very meaningful addition to your revenue, right? Ajay Bhardwaj: Well, absolutely.”
See the full cited Management analysis of Anthem Bioscienc
How durable is the business?
Anthem is expanding its technical moat into the high-growth GLP-1 (Semaglutide) space, leveraging full backward integration in fermentation which competitors lack. (1 expanding)
“Anthem will arguably have one of the strongest positions in this space, because we are fully integrated all the way backward... Anthem has developed the technology to make the fermentation fragment as well.”
See the full cited Business Model analysis of Anthem Bioscienc
Where does growth come from?
The pipeline is maturing rapidly; while late-phase molecules decreased from 10 to 6, this is because 4 successfully transitioned to commercial status, indicating a healthy conversion rate. (1 steady across 1 signal)
“The 10 late phase has gone down to 6, because 4 of them have moved to commercial now.”
See the full cited Future Growth analysis of Anthem Bioscienc
What could break the thesis?
Concentration remains high with CRDMO contributing Rs. 926 Cr (85%) of the Rs. 1,090 Cr H1 revenue, though the company is aggressively pursuing new high-growth areas like GLP-1 and Biosimilars. (1 stable)
“Our CRDMO business out of that has delivered Rs. 926 Cr of revenue and our specialty ingredients has delivered Rs. 163 Cr in revenue.”
See the full cited Risk analysis of Anthem Bioscienc
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.